| Literature DB >> 24238358 |
Yu Lu1, Zi-Hui Tang2, Fangfang Zeng2, Yiming Li2, Linuo Zhou2.
Abstract
BACKGROUND: The purpose of this study was to explore the extent of associations of cardiovascular autonomic neuropathy (CAN) with metabolic syndrome (MetS) and resting heart reate (HR), and to evaluate the predictive value of MetS combined with HR on CAN in a large sample derived from a Chinese population.Entities:
Year: 2013 PMID: 24238358 PMCID: PMC3833900 DOI: 10.1186/1758-5996-5-73
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Clinical characteristics of subjects
| Demographic information | | | | |
| N | 2096 | 1705 | 387 | |
| Age (years) | 60.42 ± 8.68 | 59.85 ± 8.64 | 62.94 ± 8.43 | <0.001 |
| Gender (male,%) | 705(33.7%) | 562(32.96%) | 143(36.95%) | 0.134 |
| BMI (kg/m2) | 24.21 ± 3.37 | 24.07 ± 3.28 | 24.84 ± 3.7 | <0.001 |
| WC (cm) | 85.07 ± 9.77 | 84.47 ± 9.62 | 87.72 ± 9.99 | <0.001 |
| SBP (mmHg) | 127.62 ± 18.77 | 126.39 ± 18.22 | 133.05 ± 20.19 | <0.001 |
| DBP (mmHg) | 79.83 ± 9.74 | 79.5 ± 9.65 | 81.31 ± 10.01 | 0.001 |
| Laboratory measurement | | | | |
| FPG (mmol/L) | 5.53 ± 1.82 | 5.4 ± 1.58 | 6.12 ± 2.54 | <0.001 |
| PBG (mmol/L) | 7.67 ± 3.63 | 7.36 ± 3.3 | 9.07 ± 4.6 | <0.001 |
| HbAlc (%) | 6 ± 1.08 | 5.89 ± 0.92 | 6.47 ± 1.54 | <0.001 |
| FINS uml | 7.19 ± 11.86 | 6.74 ± 8.03 | 9.18 ± 21.71 | <0.001 |
| IR (mmol/L) | 1.81 ± 3.31 | 1.64 ± 2.13 | 2.54 ± 6.22 | <0.001 |
| TC (mmol/L) | 5.32 ± 1 | 5.31 ± 0.98 | 5.39 ± 1.05 | 0.142 |
| TG (mmol/L) | 1.71 ± 0.98 | 1.67 ± 0.93 | 1.9 ± 1.17 | <0.001 |
| HDL (mmol/L) | 1.36 ± 0.32 | 1.36 ± 0.33 | 1.34 ± 0.32 | 0.203 |
| LDL (mmol/L) | 3.19 ± 0.77 | 3.18 ± 0.76 | 3.23 ± 0.81 | 0.229 |
| SCr (μmol/L) | 77.81 ± 26.11 | 77.65 ± 26.96 | 78.51 ± 21.98 | 0.561 |
| UA (μmol/L) | 281.21 ± 84.01 | 280.13 ± 83.47 | 285.99 ± 86.26 | 0.216 |
| HRV indices | | | | |
| HR (bpm) | 72.42 ± 10.13 | 70.77 ± 9.08 | 79.7 ± 11.26 | <0.001 |
| TP (ms2) | 873.95 ± 702.47 | 1000.63 ± 693.2 | 315.87 ± 410.75 | <0.001 |
| LF (ms2) | 190.98 ± 207.88 | 224.34 ± 215.08 | 43.97 ± 57.29 | <0.001 |
| HF (ms2) | 183.05 ± 219.43 | 215.11 ± 229.61 | 41.82 ± 59.63 | <0.001 |
| LF/HF | 1.7 ± 1.98 | 1.55 ± 1.48 | 2.37 ± 3.32 | <0.001 |
| Medical history | | | | |
| Smoking (yes,%) | 306(14.63%) | 244(14.31%) | 62(16.02%) | 0.39 |
| MetS (yes,%) | 833(39.82%) | 629(36.89%) | 204(52.71%) | <0.001 |
| DM (yes,%) | 446(21.33%) | 307(18.02%) | 139(35.92%) | <0.001 |
| HT (yes,%) | 976(46.65%) | 735(43.11%) | 241(62.27%) | <0.001 |
Note: *present the difference between subjects with and without cardiovascular autonomic neuropathy (CAN). BMI- Body mass index, WC-waist circumference, SBP- systolic blood pressure, DBP- diastolic blood pressure, FPG- fasting plasma glucose, PBG- plasma blood glucose, FINS- fasting blood insulin, IR-insulin resistance, TC- serum total cholesterol, TG- triglyceride, UA- uric acid, HDL- high-density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol, SCr- serum creatinine, HR-heart rate, TP-total power of variance, LF-low frequency, HF-high frequency, MetS- metabolic syndrome, HT- Hypertension, DM- Diabetes.
Figure 1Cardiovascular autonomic neuropathy (CAN) prevalence according to metabolic syndrome (MetS). The CAN prevalence was 14.54% and 24.49% in respective groups according to MetS. P value for trend was less then 0.001.
Figure 2Cardiovascular autonomic neuropathy (CAN) prevalence according to resting heart rate (HR). The CAN prevalence was 5.92%, 12.93%, 23.94% and 53.67% in respective groups according to HR. P value for trend was less then 0.001.
Figure 3Cardiovascular autonomic neuropathy (CAN) prevalence according to the variable of metabolic syndrome (MetS) combined with resting heart rate (MetS-HR). The CAN prevalence was 5.32%, 7.23%, 9.8%, 17.81%, 21.15%, 27.38%, 45.87% and 61.46% in respective groups according to MetS-HR. P value for trend was less then 0.001.
Univariate logistic regression analysis for cardiovascular autonomic neuropathy
| Age | 0.042 | 0.007 | <0.001 | 1.043 | 1.029–1.103 |
| Gender | 0.176 | 0.117 | 0.134 | 1.192 | 0.947–1.547 |
| BMI | 0.066 | 0.016 | <0.001 | 1.068 | 1.034–1.046 |
| WC | 0.034 | 0.006 | <0.001 | 1.034 | 1.023–1.024 |
| SBP | 0.018 | 0.003 | <0.001 | 1.018 | 1.012–1.030 |
| DBP | 0.019 | 0.006 | 0.001 | 1.019 | 1.007–1.261 |
| FPG | 0.178 | 0.027 | <0.001 | 1.195 | 1.133–1.149 |
| PBG | 0.111 | 0.014 | <0.001 | 1.117 | 1.087–1.722 |
| HbAlc | 0.392 | 0.077 | <0.001 | 1.48 | 1.271–1.026 |
| FINS | 0.014 | 0.006 | 0.015 | 1.014 | 1.003–1.159 |
| IR | 0.091 | 0.029 | 0.001 | 1.095 | 1.036–1.212 |
| TC | 0.082 | 0.056 | 0.142 | 1.086 | 0.973–1.369 |
| TG | 0.213 | 0.051 | <0.001 | 1.238 | 1.119–1.129 |
| HDL | -0.225 | 0.177 | 0.203 | 0.798 | 0.564–1.259 |
| LDL | 0.088 | 0.073 | 0.229 | 1.092 | 0.946–1.005 |
| UA | 0.001 | 0.001 | 0.216 | 1.001 | 0.999–1.108 |
| Smoking | 0.133 | 0.155 | 0.39 | 1.142 | 0.843–2.733 |
| HT | 0.779 | 0.116 | <0.001 | 2.178 | 1.736–3.248 |
| DM | 0.936 | 0.123 | <0.001 | 2.550 | 2.003–3.156 |
| HR | 0.952 | 0.068 | <0.001 | 2.590 | 2.267–2.565 |
| MetS | 0.646 | 0.114 | <0.001 | 1.907 | 1.527–1.307 |
| MetS-HR | 0.469 | 0.033 | <0.001 | 1.598 | 1.499–1.500 |
Note: Cardiovascular autonomic neuropathy (CAN). BMI- Body mass index, WC-waist circumference, SBP- systolic blood pressure, DBP- diastolic blood pressure, FPG- fasting plasma glucose, PBG- plasma blood glucose, FINS- fasting blood insulin, IR-insulin resistance, TC- serum total cholesterol, TG- triglyceride, UA- uric acid, HDL- high-density lipoprotein cholesterol, LDL- low density lipoprotein cholesterol, SCr- serum creatinine, HR-heart rate, TP-total power of variance, LF-low frequency, HF-high frequency, MetS- metabolic syndrome, HT- Hypertension, DM- Diabetes.
Multivariate logistic regression analysis for cardiovascular autonomic neuropathy
| Model 1 | HR | 0.952 | 0.07 | <0.001 | 2.592 | 2.260–2.973 |
| MetS | 0.495 | 0.126 | <0.001 | 1.641 | 1.282–2.099 | |
| Model 2 | MetS-HR | 0.477 | 0.033 | <0.001 | 1.612 | 1.510–1.722 |
Note: Model 1 and Model 2 adjusted for age, gender, smoking, SCr, UA, LDL; SCr- serum creatinine, UA- uric acid, LDL- low density lipoprotein cholesterol.
Figure 4Receiver operating characteristic curves showed the performance of resting heart rate (HR), metabolic syndrome (MetS) and categorical variable of MetS + HR in predicting cardiovascular autonomic neuropathy (CAN) prevalence in this dataset. The 95% confidence interval (CI) is given in parentheses. AUC represents area under the curve. HR: AUC = 0.719 (95% CI : 0.690-0.748), P < 0.001; MetS: AUC = 0.579 (95% CI: 0.547-0.611), P < 0.001; MetS-HR: AUC = 0.735 (95% CI: 0.707-0.763), P < 0.001.